ARTICLE | Clinical News

Dengvaxia tetravalent dengue vaccine regulatory update

December 14, 2015 8:00 AM UTC

Mexico’s Federal Commission for the Protection against Sanitary Risk (COFEPRIS) approved Dengvaxia from Sanofi’s Sanofi Pasteur vaccines division to prevent dengue fever infection in people ages 9-45 living in endemic areas. Sanofi said the approval is the first in the world for a dengue vaccine. Sanofi plans to launch the vaccine in Mexico in early 2016 but has not yet determined its price. ...